Lymphocyte responsiveness in rats was found to depend on serum prolactin levels. Blocking pituitary prolactin release with bromocriptine severely reduces lymphocyte reactivity in vitro (mixed lymphocyte reaction) as well as in vivo (graft-versus-host reaction). In addition, evidence for a prolactin/growth hormone-related mRNA species produced in mitogen-and antigen-stimulated lymphocytes has been obtained. Prolactin was shown to compete in a dose-dependent fashion with the immunosuppressant cyclosporine (cyclosporin A) for a common binding site on the surface of T lymphocytes. Further, stimulation of prolactin secretion reversed the immunosuppression induced by cyclosporine. We conclude that prolactin is involved in the maintenance of T-cell immunocompetence and that the immunosuppressive effects of cyclosporine may be mediated by the displacement of prolactin from binding sites on lymphocytes.
Prolactin is a polypeptide hormone of pituitary origin with close structural relationships to growth hormone (GH). It produces pronounced physiological effects on growth, reproduction, and osmoregulation in a wide range of species (1, 2) ; it causes a marked proliferative effect on the crop sac of pigeons (3) and in mammals is involved in the development of various glandular tissues (1, 2) . A variety of mammalian cells have receptors for prolactin, including those of the mammary gland, liver, kidney, brain, prostate, testis, and ovary (4) . Although prolactin is a pituitary hormone, proteins that react with anti-prolactin antisera appear to be synthesized in nonpituitary tissues as well (5, 6) .
Hypophysectomized rats fail to mount an immune response (7, 8) . Treatment of those animals with prolactin or GH, but not with corticotropin or other pituitary hormones, restored their immunological status (9) . Moreover, specific binding sites for prolactin have been demonstrated on human lymphocytes. The immunosuppressive peptide cyclosporine (cyclosporin A) displaces prolactin from these sites (10) (11) (12) (13) , whereas a biologically inactive derivative, cyclosporin H, does not (12) .
The purpose of this report is to present further data demonstrating the involvement ofprolactin in modulating the responsiveness ofT lymphocytes to antigenic stimulation and to describe the interactions between prolactin and cyclosporine in this process.
MATERIALS AND METHODS
Mixed Lymphocyte Reaction. Equal numbers (2.5 x 101) of murine stimulator lymphocytes (female CBA mice, Iffa Credo, Lyon, France; lymphocytes irradiated in vitro with 2000 rads; 1 rad = 0.01 J/kg) and effector lymphocytes (female BALB/c mice, Iffa Credo) from control animals or from animals treated for 7 days with bromocriptine (Parlodel; 5 mg/kg of body weight, given s.c. daily), an inhibitor of prolactin secretion, were incubated together in a final volume of 0.2 ml for 5 days. The incubation medium consisted of RPMI 1640 medium supplemented with antibiotics, 2 mM L-glutamine, and 10% fetal bovine serum. 2-Mercaptoethanol was omitted in all studies. Immunocompetence ofthe effector cells, as shown by cell proliferation in response to the allogenic stimulus, was measured by incorporation of [methyl-3H]thymidine (The Radiochemical Centre, Amersham Ltd., England; 5 Ci/mmol, 1 uCi per culture for 16 hr; 1 Ci = 37 GBq) into cellular DNA (14) .
Localized Graft-Versus-Host Reaction. Spleen cells from Wistar Furth rats (female, 6 weeks old) were injected into one hind footpad offemale (Wistar Furth x Fischer 344)F1 hybrid rats (age 6 weeks). In this assay, recipient animals do not recognize the injected cells as foreign, whereas the injected cells mount a localized immune response towards the recipient animal, causing a swelling of the popliteal lymph node (15) . Recipient animals were treated with bromocriptine (5 mg/kg per day, s.c.) for 7 days before and 4 days after the injection of the stimulator cells. The difference in weight of the left and right popliteal lymph node in untreated rats was taken as a reference for calculating inhibition occurring in animals receiving bromocriptine or cyclosporine treatment. In another experiment, bromocriptine treatment was initiated after spleen-cell injection and continued for 4 days. Studies were also done in rats receiving the immunosuppressant cyclosporine and/or a prolactin-releasing agent (compound 25-240, la,103-dimethyl-9,10-dihydroergocristine; Sandoz Ltd., Basel, Switzerland).
Plaque-Forming-Cell Assay. Mice (OF1, female, Iffa Credo) were sensitized by i.v. injection of 108 sheep erythrocytes (SRBC). Treatment of the mice with potential immuneresponse-modulating agents started 3 hr after sensitization and was continued for the next 3 days. Two days after the last treatment, the spleens were removed and splenic lymphocytes were plated on soft agar in the presence offresh antigen (SRBC) and complement. Sensitized lymphocytes release specific antibodies against SRBC, which in combination with complement causes local lysis of the surrounding SRBCsi.e., gives rise to "plaque"-formation. Each plaque represents a single antibody-secreting B lymphocyte, which forms the basis of this assay, as previously described (16 (17) . Dot Blots of Lymphocyte Cytoplasmic RNA. Cytoplasmic extracts containing RNA were prepared and bound to nitrocellulose sheets (GeneScreen, New England Nuclear, Zurich, Switzerland) according to published procedures (18) . Hybridization of suitable DNA probes to the immobilized RNAs was done as described (18), using a rat prolactinspecific probe [plasmid pPrl-1 (19) Statistics. The in vivo data were analyzed by using either the unpaired t-test or Dunnett's multirange test. Before application of the latter test, the data were analyzed for normality (Wilk-Shapiro) and subjected to a two-way analysis of variance.
RESULTS
Mixed Lyniphocyte Reaction Using Lymphocytes Obtained from Prolactin-Depleted Mice and Prolactin-Supplemented Lymphocytes. It is clear from Fig. 1 that pretreatment of BALB/c mice with the prolactin-secretion inhibitor bromocriptine markedly reduced lymphocyte responsiveness as assessed in this ex vivo assay; 40% residual lymphocyte reactivity was found under conditions where bromocriptine treatment lowered the concentration circulating prolactin below the detection level of radioimmunoassay (<1 ng/ml). Addition of exogenous rat prolactin (Table 1 ) yielded a slight stimulation of lymphocyte activity, whereas addition of porcine or human prolactin resulted in a strong inhibition of the mixed lymphocyte reaction. This inhibition was perhaps due to a competitive antagonism of the added prolactin preparation with the endogenous murine prolactin bound to lymphocyte surface receptors. Canine prolactin caused inhibition at unphysiologically high concentrations only. Ovine prolactin was Without effect. Because of the unavailability of purified mouse prolactin, it was not possible to perform the homologous experiment. In addition, we cannot rule out the possibility that some sort of contamination in the rat prolactin preparation, or for that matter in any of the prolactin preparations used, caused these in vitro effects. However, the ex vivo experiment suggests that serum prolactin may be one of the factors determining immunological responsiveness of lymphocytes.
Graft (Fig. 2) . This binding seems to be specific, since only the biologically active molecule (cyclosporin A) but not the biologically inactive analogue (cyclosporin H) was able to compete with the dansyl-labeled cyclosporine (data not shown). Labeling of T cells with cyclosporine in the presence of prolactin or prior binding of cyclosporine to T cells, followed by an incubation with prolactin, resulted in a concentration-dependent reduction in the number of [dansyl-Lys5]cyclosporine-labeled cells (Fig.   2 ). To remain within the linear portion of the cyclosporine binding curve, a concentration was chosen that caused up to 50% of the cells to be labeled and that corresponded to the Proc. Natl.,Acad. Sci. USA 83 (1986) Identification of mRNA Hybridizing with Prolactin-and GH-Specific Probes in Rat Lymphocytes After Mitogen Stimulation. In dot blot hybridization experiments, cytoplasmic RNA from lymphocytes stimulated in vitro with concanavalin A hybridized with both the prolactin-and the GH-specific probe (Fig. 3) . The hybridization signal increased 3-to 4-fold on stimulation of the cells with Con A and leveled off after 24 hr of stimulation. Characterization of the prolactin/GHspecific RNAs by blot-hybridization analysis of electrophoretically fractionated poly(A)+ RNA showed that the hybridizing RNA species were larger than the corresponding precursor and mature RNA species from pituitary (Fig. 4) . Thus, it is clear that the pituitary and the lymphocyte cytoplasmic RNAs that hybridize with the prolactin-specific probe pPrl-1 are not the same species. Dot blot analysis of rat liver RNA showed no hybridization signal with either the prolactin-or the GH-specific probe (Fig. 3) .
DISCUSSION
This study provides evidence for the involvement ofprolactin in the maintenance of T-cell immune competence. Our data show that a reduction of serum prolactin levels by bromocriptine leads to a decrease of lymphocyte responsiveness toward antigenic stimulation. This phenomenon was observed both in vitro (mixed lymphocyte reaction) and, more important, in vivo (graft-vs.-host reaction). A further indication that prolactin is involved in regulating immune responses is the presence of prolactin-binding sites on lym- phocyte cell surfaces (10-13). Displacement of bound prolactin from these sites by a biologically active cyclosporin (cyclosporine, or cyclosporin A) has been shown (12) . On the other hand, another cyclosporine, cyclosporin H, which lacks immunosuppressive activity (unpublished observations) was found to be completely ineffective in competing with prolactin for this binding site (12) . The present study also (21) , was electrophoresed in 1.5% agarose under denaturing conditions as described (22) . Nitrocellulose blots were incubated with 32P-labeled nick-translated plasmid pPrl-1 (19) as described (21) (Table 3) in cyclosporine-treated animals. T-cell interactions, as in cellular immune responses and as seen in the graft-vs.-host reaction, were partially inhibited by lowering circulating prolactin levels. Again, immune responsiveness in cyclosporine-treated (immunosuppressed) animals was restored by raising circulating prolactin levels. That reduction of circulating prolactin by bromocriptine did not reduce the number of antibody-producing cells in response to the injection of SRBC might be explained if the number of lymphocyte prolactin receptors is directly related to the concentration of circulating prolactin (23) .
Since we were not able to completely abolish the T-cellmediated immune response, even after reducing circulating prolactin to virtually undetectable levels with bromocriptine, we investigated whether lymphocytes themselves could produce prolactin (or a functionally related product) on antigenic stimulation. Dot blot hybridization showed that cytoplasmic RNA from lymphocytes hybridized with both prolactin and GH cDNA probes. Lymphocytes from either rats (Fig. 3) or mice (data not shown) reacted with an increase in these RNAs after mitogenic stimulation. We therefore suggest that the ability of T lymphocytes to respond fully to antigenic stimulation may depend on the presence of prolactin, of pituitary origin, bound to receptors on their outer membrane. On presentation of antigen these lymphocytes then produce a secondary signal in a form of a prolactin/GH-related polypeptide that can amplify either the response of the same cell to produce lymphokines (autocrine action), or the mitogenic response of neighboring lymphocytes (exocrine action), or both.
Our results also suggest that cyclosporine may exert its immunosuppressant action by displacing pituitary prolactin, and perhaps also the prolactin/GH-related polypeptide, from 
